Skip to main content
. 2023 Jul 17;20(1):103–111. doi: 10.1002/alz.13368

FIGURE 3.

FIGURE 3

In the biomarker discovery phase, low‐TDP and mid‐TDP proteoforms distinguished FTLD‐TDP from controls as demonstrated by (A) normalized relative peak area and (B) receiver operating characteristics curve analysis